Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment…
<!-- Name:DistributionId Value:8788554 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:ACER
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant)…
<!-- Name:DistributionId Value:8747527 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of…
NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies…
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering…
NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and…
Acer Therapeutics Announces University of North Carolina Receives Department of…
$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored…
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of…
NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today…
Acer Therapeutics to Participate in August and September 2022 Investor Conferences
NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies…
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has…
GENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer…
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the…
NEWTON, Mass. and GENEVA, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX:…
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for…
NEWTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies…